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Abstract
Background: Prenatal urinary concentrations of phthalates in women participants in an urban birth cohort were
associated with outcomes in their children related to neurodevelopment, autoimmune disease risk, and fat mass at 3,5,7,
and 8 years of life. Placental biomarkers and outcomes at birth may offer biologic insight into these associations. This is
the first study to address these associations with candidate genes from the phthalate and placenta literature, accounting
for sex differences, and using absolute quantitation methods for mRNA levels.
Methods: We measured candidate mRNAs in 180 placentas sampled at birth (HSD17B1, AHR, CGA, CYP19A1, SLC27A4,
PTGS2, PPARG, CYP11A1) by quantitative PCR and an absolute standard curve. We estimated associations of loge mRNA
with quartiles of urinary phthalate monoesters using linear mixed models. Phthalate metabolites (N = 358) and mRNAs
(N = 180) were transformed to a z-score and modeled as independent, correlated vectors in relation to large for
gestational age (LGA) and gestational diabetes mellitus (GDM).
Results: CGA was associated with 4 out of 6 urinary phthalates. CGA was 2.0 loge units lower at the 3
rd vs. 1st quartile of
mono-n-butyl phthalate (MnBP) (95% confidence interval (CI): −3.5, −0.5) in male placentas, but 0.6 loge units higher
(95% CI: −0.8, 1.9) in female placentas (sex interaction p = 0.01). There was an inverse association of MnBP with PPARG in
male placentas (−1.1 loge units at highest vs. lowest quartile, 95% CI: −2.0, −0.1). CY19A1, CYP11A1, CGA were associated
with one or more of the following in a sex-specific manner: monobenzyl phthalate (MBzP), MnBP, mono-iso-butyl
phthalate (MiBP). These 3 mRNAs were lower by 1.4-fold (95% CI: −2.4, -1.0) in male GDM placentas vs. female and non-
GDM placentas (p-value for interaction = 0.04). The metabolites MnBP/MiBP were 16% higher (95% CI: 0, 22) in GDM
pregnancies.
Conclusions: Prenatal concentrations of certain phthalates and outcomes at birth were modestly associated with
molecular changes in fetal placental tissue during pregnancy. Associations were stronger in male vs. female placentas,
and associations with MnBP and MiBP were stronger than other metabolites. Placental mRNAs are being pursued further
as potential mediators of exposure-induced risks to the health of the child.
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Background
Urinary phthalate metabolites, which are detectable in
99–100% of residents in the United States, enter our bod-
ies through dietary ingestion [1, 2] inhalation [3], and der-
mal uptake [4]. Exposure levels vary by age, race, and
income [5–7]. Urinary phthalate concentrations in preg-
nant women have been associated with short-term effects
on their pregnancies (timing of labor, biomarkers related
to risk of preeclampsia) [8–10] and with long-term effects
in their children (future reproductive function, asthma
and eczema, fat mass, neurocognitive and neurobehavioral
outcomes) [11–13]. The role of the human placenta and
the mechanisms that might explain these effects are not
well studied or understood.
Consideration of the placenta can grant temporal and
spatial precision to estimates of association given the
placenta’s physical location between maternal circulating
phthalates and the developing embryo/fetus at precisely
the time when organs are developing and cells and tis-
sues are undergoing programming. With this knowledge,
we can develop better measures of the placental re-
sponse to the exposure, and potentially within an early
enough timeframe to alter the short-term risks to the
pregnancy and the long-term risks to the child.
Our pilot study demonstrated associations between
maternal urinary phthalates and placental mRNAs, but
did not account for sex differences in these associations
[14]. Two in vitro studies measured mRNA changes in
human placental cells in response to doses of mono-2-
ethylhexyl phthalate (MEHP) [15, 16]. These studies did
not account for sex differences and the dose ranges were
50–200 fold higher than what are measured in the urine
of pregnant women. Our aim was to analyze these rela-
tionships in the context of commonly measured phthal-
ate levels in pregnant women, and to account for sex
differences.
The recent emphasis on sex differences in placental re-
sponses (reviewed in [17]) underlines the fact that the pla-
centa is fetal, and not maternal, tissue in its origin,
function, and molecular profile. There is a need currently
for human placental data and unifying theories as to how
the molecular machinery of a female vs. a male placenta
might differ at baseline, behave differently in response to a
chemical exposure, and differentially alter fetal develop-
ment. Two cellular mechanisms, one involving autophagy
and another involving receptor isoforms, have been identi-
fied that explain why the response to a maternal exposure
(adiposity, cortisol) might differ between a female vs. a
male placenta, i.e. effect modification by sex [18, 19].
There are similarly reasons to suspect that the placenta
may play a different role in regulating aspects of fetal de-
velopment in a male vs. a female [20]. Canonical placental
functions (nutrition, gas exchange, etc.) play an important
role after 10 weeks of pregnancy, or the end of
organogenesis [21]. However, prior to this point, the pla-
centa may be synthesizing and secreting molecules neces-
sary for proper, sex-specific, tissue differentiation [22].
We measured the association of 6 maternal urinary
phthalate metabolite concentrations in late pregnancy with
the mRNA concentrations of 8 candidate genes in placental
tissue biopsied at birth. These placentas were sampled from
the same pregnancies in which associations have been re-
ported between prenatal phthalate concentrations and indi-
cators of neurodevelopment at 3 and 7 years of age [23,
24]; with the risk of asthma at 8 years of age [25]; and the
risk of obesity from 4 to 7 years [26, 27]. These candidate
genes were chosen based on a priori knowledge of the tran-
scriptional effects of phthalates, their expression in the hu-
man placenta (reviewed in [14]), and associations with
placentally-mediated pathologies such as preeclampsia
(HSD17B1, CYP19A1, CGA, AHR) [28–31], gestational dia-
betes (PPARG, CGA) [29, 32], fetal growth restriction
(AHR) [28], and fetal programming (SLC27A4) [33]. A sec-
ondary aim was to evaluate the independent relationships
of the phthalates and placental biomarkers with these types
of outcomes at birth (fetal size, gestational diabetes).
Methods
Subjects
African American and Dominican American pregnant
women (N= 358) were enrolled in the phthalate substudy of
the Mothers and Newborns Study of the Columbia Center
for Children’s Environmental Health (CCCEH) [34]. A subset
of these women donated placental tissue at birth (180). They
delivered at one of three community hospitals in New York
City between 2002 and 2006. The present study is a full ana-
lysis of the pilot placenta study previously described [14].
CCCEH participants gave informed consent to participation
including collection of urine, sampling of the placenta at de-
livery, and access to prenatal and birth records. Maternal
and pregnancy characteristics and birth/neonatal outcomes
were derived from the study prenatal questionnaire, the
mother’s medical record, and/or the baby’s birth record.
Large for gestational age (LGA) was calculated with U.S. ref-
erence birth weight values by race/ethnicity and sex. [35]
Gestational diabetes was ascertained by combined self-report
from the prenatal questionnaire in the third trimester and
from the birth record given potential inconsistencies across
reporting on the birth record at the three hospitals. The
CCCEH study and subsequent data analysis was approved
by the Columbia University Medical Center Institutional Re-
view Board (IRB) and the University of Pittsburgh IRB.
Placental samples
Biopsies were taken from the fetal side of the placenta
by cutting into the chorionic plate and sampling of fetal
chorionic villi, and preserved in RNALater (Qiagen,
USA). To capture variability in gene expression within
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the placenta, one sampling site was close to the umbilical
cord insertion point and one close to the outer margin of
the placenta [36]. We generated gene expression data for
2 biopsies from each of 164 placentas. For some placentas,
either tissue was unavailable or the tissue quality and/or
quantity were insufficient for analysis, thus, in 12 placen-
tas we relied on 1 biopsy, while we had more than 2 biop-
sies from 4 placentas. Samples were preserved in
RNALater (Qiagen, USA) and stored at -80C. Based on
histologic analysis, there was minimal contamination of
the biopsies with cells from the chorionic membrane and
basal plate [36].
RNA from placental tissue biopsies
Total RNA was isolated from each tissue sample in two
batches. The first batch of 55 placentas was analyzed as
described previously [14]. The second batch was analyzed
using automated methods. Tissue was homogenized using
the Tissue Lyser (Qiagen, USA) according to the supplier’s
protocol. RNA isolation was carried out using the QIA-
cube (Qiagen, USA). RNA quality was assessed by separ-
ation and visualization of the 28s and 18s ribosomal RNA
bands on an analytical agarose gel and quantitated by
spectrometry. RNA was reverse transcribed to cDNA
using Superscript II (Life Technologies, USA).
Gene expression in placental tissue biopsies
We selected 8 candidate genes whose expression has
been shown in prior experimental studies to be affected
by one or more of the 6 phthalates analyzed, and chori-
onic gonadotropin alpha [CGA] was added because of its
specificity to the human placenta and known variability
across placental tissue [37]. The candidate genes (17beta
hydroxysteroid dehydrogenase type 1 [17BHSD1], aryl-
hydrocarbon receptor [AHR], aromatase [CYP19A1],
CGA, P450 cholesterol side chain cleavage enzyme
[CYP11A1], peroxisome proliferator activated receptor
gamma [PPARG]) and details of the qPCR primers were
described in detail previously [14]. A transcript of 114
base pairs (bp) for the fatty acid transport protein 4
(SLC27A4) was added [38], as well as a 204 bp transcript
for COX2 [PTGS2]. PTGS2 was only measured in 124 of
the samples. 18 s (RN18S1) mRNA was measured in all
samples as an internal control. Plates were run sequen-
tially on the ABI 7900HT quantitative polymerase chain
reaction analyzer (Applied Biosystems, USA). Each sam-
ple was run in duplicate, and values not falling within
50% of their mean were rerun. Specificity of the PCR
product was evaluated using the melting curve and by
running a 2% agarose gel to visualize the PCR product.
Absolute quantitation of mRNA concentration in the
original sample was achieved using a standard curve
generated for each batch, as described previously [39].
The R2 for the standard curve was between 0.98 and
1.00; the plate was rerun if it was < 0.95. mRNA concen-
trations were log-transformed before analysis.
Urinary phthalates
Maternal urine samples were collected from participants
at a mean gestational age of 34 weeks (standard deviation
3.0 weeks). Phthalates were measured at the Centers for
Disease Control and Prevention and included a panel of
phthalate metabolites, of which we used the 6 most
frequently detected monoesters, i.e., mono-n-butyl phthal-
ate (MnBP, 100%), monobenzyl phthalate (MBzP, 100%),
mono-2-ethylhexyl phthalate (MEHP, 84%), monoethyl
phthalate (MEP, 100%), and mono-iso-butyl phthalate
(MiBP, 99%). In a separate analysis, we used the following
oxidative metabolites of di-2-ethylhexyl phthalate:
mono-2-ethyl-5-oxohexyl (MEOHP, 100%), mono-2-ethyl-
5-hydroxyhexyl phthalate (MEHHP, 100%), mono-2-ethyl-
5-carboxypentyl phthalate (MECPP, 100%); and an oxida-
tive metabolite of di-n-butyl, di-iso-butyl and other
higher molecular weight phthalates, mono-3-carboxy-
propyl phthalate (MCPP, 94%) [40, 41]. The analysis
involved enzymatic deconjugation of phthalate glucuro-
nides, solid-phase extraction, separation by HPLC, and
detection by isotope-dilution tandem mass spectrom-
etry [42]. The limits of detection (LODs) were MEHP,
3.2 nM; MnBP, 1.8 nM; MBzP, 0.43 nM; MEP, 2.1 nM;
MiBP, 1.0 nM; MEOHP, 1.5 nM; MEHHP, 1.1 nM;
MECPP, 0.8 nM; MCPP, 0.6 nM. To analyze the DEHP
oxidative metabolites, we summed the molar quantities
of MEOHP, MEHHP, and MECPP (DEHP-oxo). For
statistical analysis, concentrations below the LOD were
assigned a value equal to the LOD divided by the
square root of two. Specific gravity was measured using
a PAL 10-S hand-held refractometer (Atago, USA).
Statistical analysis
Association with placental tissue mRNAs
Urinary phthalate nM concentrations were modeled as
quartiles and gene expression values were natural log-
transformed before analysis. To estimate associations be-
tween maternal urinary phthalate concentrations and
loge mRNA levels, we fit mixed effects models to ac-
count for the correlation of multiple samples within a
placenta. We simultaneously included multiple phtha-
lates in all models for two reasons: a) to control for
inter-individual differences in phthalate metabolism and
excretion, and b) to estimate independent effects of the
5 phthalate monoesters. MnBP/MiBP, MBzP, MEHP, and
MEP estimates were adjusted for each other. MnBP and
MiBP were each modeled separately given their high
correlation (r = 0.77). Phthalate metabolite formation
proceeds as: phthalate diester > hydrolysis by non-
specific lipases > phthalate monoester metabolites> > ac-
tivation of polymorphic enzymes in the liver and
Adibi et al. Environmental Health  (2017) 16:35 Page 3 of 14
placenta to metabolize and excrete xenobiotics> >
phthalate oxidative metabolites [43]. In the case of
pregnancy, this transformation process may be con-
founded by maternal genetics, health and placental
function, rendering the oxidative metabolites a subopti-
mal proxy for DEHP:MEHP exposure and biologic
action [44]. Combining the two types of metabolites
into a single molar sum may reduce precision in the
DEHP:MEHP exposure estimate. To estimate asso-
ciations with monoesters, we did not adjust for the
downstream oxidative metabolites. To estimate corre-
lations of the oxidative metabolites and gene expres-
sion, we used the molar sum of the DEHP oxidative
metabolites (DEHP-oxo) and co-adjusted for the
monoesters. To rule out potential multiple co-
linearity of the single measures of phthalate metabo-
lites in relation to a mean gene expression per pla-
centa, we fit linear regression models and examined
the variance inflation factor and the condition index
output as co-linearity diagnostics. Models were ad-
justed for 18s mRNA concentration to control for
variability in RNA quality and quantity going into the
reaction, as well as a term for technician who carried
out the sampling, the qPCR batch, urinary dilution
(z-score of specific gravity), sex of the neonate and
body mass index (BMI) at the start of pregnancy. The
types of confounding that were evaluated include maternal
hydration and kidney function (i.e. specific gravity) [45],
maternal adiposity and weight, time elapsed between de-
livery and placental tissue sampling, maternal demograph-
ics (race, education, marital status, income), maternal
medical and reproductive history, year of delivery, and
maternal medications and supplements. Sex of the neo-
nate was imputed for the 2 missing subjects, based on pla-
cental hormone gene expression values. For the analysis of
associations between urinary phthalates and outcomes in
the full sample, we evaluated the following types of con-
founding: year and season of birth, maternal size and
weight gain, maternal demographics, smoking, chronic
disease, and reproductive history. Variables that were sig-
nificantly correlated with phthalates in the presence of the
birth outcome variable were retained in the model. If there
was 10% or greater missingness in a variable, it was ex-
cluded from the analysis. Given the larger sample size, we
allowed for small differences in covariates by model in
order to address differences in sources of exposure and
biologic action between the metabolites. For each phthal-
ate and gene association, we fit a model to calculate the
P-value for the interaction of phthalate concentrations
and sex of the placenta. Using parameters from this
model, we computed sex-specific beta coefficients and
confidence intervals with quartile 1 as the referent
within sex, and female quartile 1 as the referent for
male quartile 1.
Associations with birth outcomes
We estimated associations of urinary phthalate bio-
markers with LGA and GDM outcomes in the full co-
hort (N = 358), and mRNA biomarkers with the same
outcomes in the placenta substudy (N = 180). We com-
pared biomarker mean values across the outcomes, in-
stead of calculating odds ratios given the relatively small
sample sizes for rare outcomes. For the 2 urinary phthal-
ate metabolites that originate from DnBP and DiBP
(MnBP, MiBP), and separately for DEHP-oxo and MCPP,
z-score means were modeled as a correlated vector of
responses within each subject, adjusting for phthalate
concentrations (MBzP, MEHP, MEP) and other covari-
ates (18s mRNA, qPCR batch, technician, sex of the
baby and BMI). The mixed effects model approach al-
lows for the analysis of the combined mean phthalate
concentration while also taking into account differences
between phthalates, and simultaneously adjusting for the
within person phthalate correlations [46]. We assumed
equal correlation between any two phthalates measured
within a single person. This approach has been used in
the setting of factor analysis, where multiple exposures
or biomarkers are first standardized as z-scores to put
them on the same scale, and then factors are derived
based on the inter-correlation among these standardized
measures of exposures [47]. To estimate differences in
the other 3 phthalates (MBzP, MEHP, MEP) that origin-
ate from different phthalate diesters, we modeled them
as individual metabolites.
In the subset with placental mRNA data (N = 180), we
applied a similar strategy to estimate correlations between
placental mRNAs and birth outcomes that relate to
placental function, independently of phthalates, and
additionally adjusted for placental-fetal sex, urinary dilu-
tion, 18s RNA mRNA (housekeeping gene), body mass
index at the beginning of pregnancy, qPCR batch, techni-
cian, urinary dilution, and year of sample. We estimated
percent change between the cases and the non-cases using
the model intercept and the beta coefficient for the
outcome. We did not adjust for multiple comparisons
given the exploratory nature of the analysis. Analyses were
carried out using SAS 9.2 (SAS, USA).
Results
The 180 placenta donors from CCCEH generally resem-
bled the larger cohort of 358 women with urinary phthal-
ate measures, from which they were sampled [3] (Table 1);
yet they also differed from the larger sample as 1) the
mothers carrying females had lower BMI’s than the
mothers carrying males, 2) there was a lower proportion
of African-American vs. Dominican participants, and 3)
mothers carrying males had a higher prevalence of LGA
births than mothers carrying females. The geometric
mean phthalate monoester concentrations were (highest
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to lowest): MEP (1.3 μM) >MnBP (174 nM) >MBzP
(81 nM) >MiBP (48 nM) >MEHP (18 nM).
Of the 40 tests to identify main effect associations of
urinary phthalate monoester quartiles and placental
mRNA, 2 tests (5%) reached statistical significance at p <
=0.05: MiBP and PTGS2, MEP and PPARG (data not
shown). In the 40 tests to assess phthalate and sex interac-
tions, 8 (20%) reached statistical significance at p < 0.05.
CGA mRNA was associated with 4 of the 5 monoester
phthalates, and also with DEHP-oxo (Table 2, Additional
file 1: Table S1). Associations differed significantly by sex
for three of the genes: CGA (Fig. 1), CYP19, and CYP11A1
(Table 2, Fig. 2). MnBP associations with CGA mRNA were
opposite in direction between males and females. CGA ex-
pression was 2.0 loge units lower (95% CI: −3.6, −0.5) in
male placentas at the 3rd quartile (175–357 nM) of MnBP,
compared to the first quartile (0–95 nM). This translates as
an 82% decrease (95% CI: −144, −20). In the female placen-
tas, CGA expression was 0.6 loge units higher in the 3rd vs.
the 1st quartile, but the confidence interval included zero
(95% CI: −0.8, 1.9). This translates as a 24% increase (95%
CI: −30, 78, p-value for sex interaction = 0.01). Results for
the 4 mRNAs that did not differ by sex in their phthalate
associations are reported in Additional file 2: Table S2. The
associations were overall stronger in male placentas than in
females, except for 17BHSD1. In the male placentas, gene
expression was generally lower with higher phthalate con-
centration, except for SLC27A4 (fatty acid transport protein
4). Other strong inverse, exposure-response associations
were observed for MiBP and CGA and MnBP and PPARG
in male placentas. These were of similar magnitude as
reported above: 64-77% decrease from the first quartile of
exposure. Alternative approaches (log linear, quintiles,
spline regressions) for considering phthalate concentrations
did not change the conclusions.
In Additional file 1: Table S1, we present associations of
the oxidative metabolites and the 4 mRNAs that differed
by sex. DEHP-oxo was more strongly associated than
MEHP with CYP19A1 (p = 0.09 vs. p = 0.46), AHR (p =
0.09 vs. p = 0.90), and CYP11A1 (p = 0.02 vs. p = 0.11),
Table 1 Characteristics of the Columbia Center for Children’s Environmental Health (CCCEH) placenta and phthalate substudies
Placenta substudy (N = 180) Phthalate study (N = 358)
Mean (SD) Mean (SD)
Female Male Female Male
Maternal age (yr) 26.0 (4.9) 25.9 (4.5) 25.4 (4.9) 25.6 (4.8)
Gestational age at delivery (wks) 39.4 (1.6) 39.4 (1.6) 39.5 (1.5) 39.4 (1.5)
Body mass index at the start of pregnancy 25.8 (6.8) 27.3 (7.3) 26.0 (6.6) 26.8 (7.6)
N (%) N (%)
Female Male Female Male
N 90 (50) 90 (50) 189 (53) 169 (47)
Vaginal births 63 (73) 56 (67) 137 (75) 112 (70)
Parity
0 livebirths 35 (39) 39 (44) 87 (44) 72 (43)
1 livebirths 39 (44) 28 (31) 62 (32) 54 (32)
> 1 livebirths 15 (17) 22 (25) 43 (23) 43 (25)
Ethnicity
Dominican 67 (74) 73 (82) 130 (69) 121 (72)
African American 23 (26) 16 (18) 59 (31) 48 (28)
Education
< High school 4 (4) 7 (8) 6 (3) 10 (6)
High school or equivalent exam 62 (69) 56 (63) 140 (74) 112 (66)
> High school 24 (27) 26 (29) 43 (23) 47 (28)
Marital status
never married 65 (72) 50 (56) 134 (72) 102 (60)
widowed, divorced, separated 5 (6) 9 (10) 8 (4) 13 (8)
married 20 (22) 30 (34) 47 (25) 54 (32)
Large for gestational age 3 (4) 11 (13) 13 (7) 15 (9)
Gestational diabetes 6 (7) 8 (9) 11 (6) 12 (7)
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ab
Fig. 2 Summary of the reported associations. a Associations of phthalate monoesters, placental mRNAs (sex-specific), and outcomes. b Associations of
phthalate monoesters with placental mRNAs in male pregnancies only or in female pregnancies only, and associations of placental mRNAs with outcomes.
Shaded metabolites and the 2 groups of genes were modeled as correlated vectors. MnBP and MiBP concentrations were 16% higher (95% CI 0, 32) in
GDM pregnancies vs. non-GDM pregnancies
a b c
d e f
Fig. 1 Sex-specific associations of maternal urinary phthalate metabolites, expressed as quartiles, with loge chorionic gonadotropin alpha (CGA)
mRNA expression (mean, SE) in placental biopsies sampled at delivery. a Mono-n-butyl phthalate b Monobenzyl phthalate c Mono-iso-butyl
phthalate d Mono-2-ethylhexyl phthalate e Molar sum of DEHP oxidative metabolites f Monoethyl phthalate
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based on the p-value for the sex interaction. In male pla-
centas, the DEHP-oxo and CYP19A1 and CGA associa-
tions were strongly inverse. In female placentas, the
direction of the DEHP-oxo and mRNA association
switched direction as compared to MEHP. The oxidative
metabolite MCPP was generally less strongly associated
with the mRNAs than the monoesters MiBP and MnBP.
Relative to MiBP, urinary MnBP was higher by 15%
(95% CI: −4, 33, p-interaction = 0.03) in LGA pregnan-
cies vs. non-LGA pregnancies (Table 3). The oxidative
metabolite, MCPP, was elevated by 24% (95% CI: 8, 60)
in the LGA pregnancies. MEHP, DEHP-oxo, MBzP, and
MEP were not associated with either outcome.
We applied a similar method to estimate associations
of the outcomes with correlated vectors of mRNAs. We
grouped the mRNAs into those that were associated
with phthalates differently in males and females (CYP19,
CYP11A1, CGA), and those that were not (PPARG,
AHR, HSD17B1, SLC27A4) (Additional file 3: Table S3,
Fig. 2). There were only 3 female vs. 11 male LGA preg-
nancies in the placenta substudy (Chisq p = 0.02). The
LGA placentas had 1.5-fold lower (95% CI: −2.8, −1.1)
expression of the mRNAs: PPARG, AHR, HSD17B1 and
SLC27A4. The two groups of mRNAs in GDM placentas
were lower in male vs. female births. According to
mRNA-specific calculations, CGA was lower in LGA
placentas, but did not differ in GDM vs. non-GDM
placentas. We did not observe associations of phtha-
lates or mRNAs with small for gestational age placentas
(8% of female births, 6% of male births).
Discussion
In the course of this study, we made important observa-
tions that have informed our understanding of the hu-
man placental response to phthalate exposure. First,
associations, in some cases, differed by the sex of the
placenta. This was non-intuitive as the placenta anatom-
ically, morphologically and functionally does not differ
by sex. From an evolutionary point of view, it is also
non-intuitive [48]. If the placenta performs markedly
better or worse in response to environmental stress in
one sex or another, we postulate that his could result in
an imbalanced sex ratio and lower reproductive fitness.
Secondly, we found that the gene for a key placental
hormone hCG that is involved in most physiologic pro-
cesses in pregnancy [49] and with normal sex differenti-
ation of the male fetus [22], may be a target of phthalate
exposure. CGA, one of the genes that encodes hCG, was
associated with the greatest number of phthalate metab-
olites. Thirdly, we observed a small number of associa-
tions of these gene expression biomarkers and the
urinary phthalates with outcomes at birth potentially re-
lated to obesogenic actions and/or endocrine functions
of the placenta. Taken together, this argues for more
consideration and efforts to measure and model the mo-
lecular response of the placenta as mediator of the ef-
fects of phthalate exposures on the short-term outcome
of the pregnancy and the long-term health of the child.
The sex imbalance in the phthalate associations that we
measured might be due to sampling variability, or the
slightly greater size of male placentas at birth. It may also
relate to the general hypothesis that male fetuses and pla-
centas are more susceptible to adversity in utero [50, 51].
The mRNA levels (HSD17B1, CYP19A1, CGA, PPARG)
were generally higher in males vs. females at the lowest
quartile of phthalate, and those differences were either lost
or reversed over the range of phthalates. mRNA levels were
inversely correlated with phthalates in male placentas. As-
sociations in female placentas were generally positive and
significant in the case of high MBzP concentrations. This is
similar to trends identified between placental concentra-
tions of brominated flame retardants and placental thyroid
hormones [52]. We do not infer from our finding that
MBzP is toxic in one sex (i.e. lower gene expression)
and beneficial (i.e. higher gene expression) in another,
but instead postulate that the mechanisms of phthal-
ate action may differ in the two sexes. Similarly,
mechanisms that regulate hormone synthesis may dif-
fer between male and female placentas. In this study,
correlations between exposure, placental mediators,
and birth outcomes were generally stronger in males
than females. However, in subsequent studies where
we have dosed placental tissue with phthalates, the
molecular response of the female was stronger (Adibi
et al. in review). In a recently published longitudinal
analysis, urinary MiBP was lower in preeclamptic fe-
male pregnancies vs. controls [53]. For the DEHP me-
tabolites, investigators observed positive relative risks
that were stronger in relation to phthalates measured
later vs. earlier in pregnancy. Both sets of findings re-
quire caution in interpretation, given the possibility
that the urinary metabolite levels might be a result
rather than a cause of the placental pathology. Similar
to our study, effect sizes for the monoester metabo-
lites were modest (i.e. less than 2-fold), and confi-
dence intervals were wide given the challenge of
studying rare outcomes in a cohort setting.
MnBP and MCPP levels in this study were higher in
the mothers of babies born large for gestational age.
This is consistent with the idea that phthalate exposure
in early pregnancy can alter fetal/placental metabolic
programming, and the finding that prenatal MCPP in
these same pregnancies was associated with 2-fold
higher risk of obesity from 4 to 7 years of life [26]. Even
though we and others treat MCPP as a metabolite of
DBP, we do not know its primary source, why it is rising
in the population, and whether its biologic action resem-
bles the monoesters [7, 40, 41]. Phthalates such as
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Table 3 Z-score differences in urinary phthalates between pregnancies with and without complications
Model Parameter Large for gestational age (LGA) Gestational diabetes
mellitus (GDM)
1.1 Intercept −1.69 (−2.18, −1.21) −1.45 (−1.86, −1.05)




1.2 β (MnBP) 0.25 (−0.06, 0.55) 0.26 (−0.03, 0.55)
β (MiBP) −0.02 (−0.23, 0.19) 0.20 (−0.05, 0.44)
p (interact) = 0.03* p (interact) = 0.75
1.3 Female β (mean) −0.09 (−0.39, 0.21) 0.22 (−0.08, 0.52)
Male β (mean) 0.27 (−0.01, 0.55) 0.24 (−0.10, 0.58)
p (interact) = 0.08 p (interact) = 0.95
2.1 Intercept −1.43 (−1.77, −1.08) −1.62 (−2.00, −1.24)




2.2 β (ΣDEHP oxidative) −0.11 (−0.28, 0.07) −0.01 (−0.24, 0.22)
β (DBP oxidative) 0.34 (0.11, 0.57)* 0.25 (0.00, 0.49)*
p (interact) < 0.0001 p (interact) = 0.05
2.3 Female β (mean) 0.07 (−0.14, 0.27) −0.02 (−0.31, 0.26)
Male β (mean) 0.16 (−0.10, 0.42) 0.25 (−0.01, 0.51)
p (interact) = 0.60 p (interact) = 0.16
3.1 Intercept −1.18 (−1.90, −0.46) −1.23 (−1.93, −0.52)




3.2 Female: β (MBzP) −0.06 (−0.46, 0.35) −0.28 (−0.76, 0.19)
Male: β (MBzP) 0.22 (−0.21, 0.64) −0.24 (−0.67, 0.19)
p (interact) = 0.36 p (interact) = 0.60
4.1 Intercept −0.27 (-0.97, 0.42) −1.05 (−2.79, 0.69)




4.2 Female: β (MEHP) −0.24 (−0.69, 0.22) −0.35 (−0.87, 0.16)
Male: β (MEHP) −0.28 (−0.78, 0.22) −0.27 (−0.76, 0.21)
p (interact) = 0.90 p (interact) = 0.53
5.1 Intercept −0.68 (1.24, −0.12) −0.80 (−1.33, −0.62)




5.2 Female: β (MEP) 0.14 (−0.33, 0.62) 0.17 (−0.33, 0.68)
Male: β (MEP) −0.02 (−0.47, 0.42) −0.11 (−0.59, 0.37)
p (interact) = 0.29 p (interact) = 0.16
Beta coefficients (z-scores, 95% confidence intervals) represent the difference in urinary phthalate concentrations between women with and without
pregnancy complications
Abbreviations: MnBP Mono-n-butyl phthalate, MBzP Monobenzyl phthalate, MEHP Mono-2-ethylhexyl phthalate, MEP Monoethyl phthalate, MiBP Mono-iso-butyl
phthalate, MCPP Mono-3-carboxypropyl phthalate, DEHP di-2-ethylhexyl phthalate, DBP DiButyl phthalate
aAll models were adjusted for urinary dilution and placental-fetal sex. In Model 1, monoester metabolites of di-n-butyl and di-iso-butyl phthalate were modeled as
a correlated vector, with adjustment for log urinary concentrations of MBzP, MEHP, and MEP. In Model 2, the sum of DEHP oxidative metabolites (MEOHP, MEHHP,
MECPP) and the DBP oxidative metabolite MCPP were modeled as a correlated vector, with adjustment for urinary concentrations of MnBP, MiBP, MBzP, MEHP,
and MEP. In Models 3–5, each metabolite was modeled separately and adjusted for log urinary concentrations of MnBP, MBzP, MEHP, and MEP
Model specific covariates
LGA: Model 1 (MnBP/MiBP): year of birth, season of birth, parity, weight gain (tertiles); Model 2 (oxidative metabolites): year of sample, body mass index at the
start of pregnancy (tertiles). Model 3 (MBzP): maternal age, weight at the start of pregnancy, education; Model 4 (MEHP): weight at the start of pregnancy, year of
birth; Model 5 (MEP): body mass index at the start of pregnancy (tertiles), parity, household income
GDM: Model 1 (MnBP/MiBP): year of birth, season of birth, parity; Model 2 (oxidative metabolites): year of sample, season of birth; Model 3 (MBzP): maternal age,
weight at the start of pregnancy; Model 4 (MEHP): weight at the start of pregnancy, year of birth, maternal age, second hand cigarette smoke, elective abortions;
Model 5 (MEP): parity, household income. *p < =0.05
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MCPP, MnBP and MiBP may be working through pro-
obesogenic [54], lipid transport [55], or glucose metabol-
ism mechanisms [56] to increase fetal body mass at any
time point in pregnancy. In our data, all quartiles of
MnBP and the third quartiles of MiBP and MCPP were
strongly associated with decreased levels of placental
PPARG in male placentas, a transcriptional regulator of
adipogenesis that has been implicated in obesogenic ef-
fects of endocrine disruptors [57]. Male PPARG mRNA
was also lower in LGA cases vs. non-cases. In another
birth cohort, first trimester MCPP concentrations were
associated with circulating levels of leptin in male fe-
tuses [58]. These findings support the idea of a
phthalate-induced, sex-specific effect on PPARγ-
regulated metabolic programming, possibly a shared ef-
fect between the placenta and the fetus [59]. Another in-
teresting parallel between our study and one of the
follow-up studies on fat mass is that we both observed
significant sex interactions for MnBP and MiBP in which
the beta coefficients were positive for females and nega-
tive for males, but did not reach significance in the fe-
males [27]. Similar to our study, they saw stronger
relationships with the non-DEHP metabolites when ana-
lyzed as a joint exposure.
To address the within-person, autocorrelation in urin-
ary and placental biomarkers, we implemented an ap-
proach of combining these features as a correlated
vector, after transformation to a z-score. Even though
combined as a correlated vector, we still had the ability
to estimate the individual effects of each metabolite or
each mRNA.
The significance of phthalate metabolism and elimin-
ation as a potential important confounder or mediator
of urinary concentrations and placental/birth outcomes
remains largely unstudied, and not well addressed in
current modeling methods. Originally the urinary mono-
esters were proposed as a proxy for phthalate diester
exposure [60]. Soon after, the oxidative metabolites of
DEHP were proposed as a better proxy given higher
abundance in urine and longer half-life [61]. Placental
mRNAs, measured as primary endpoints in this study,
may also be involved in phthalate metabolism and the
production of oxidative metabolites [62]. For this reason,
we decided to focus our analysis on the monoesters for
greater precision in the diester:monoester exposure
assessment. Interestingly, the DEHP-oxo had stronger sex
interactions than MEHP in relation to the CYP450
enzymes CYP19A1 and CYP11A1 and the AHR, all genes
involved in xenobiotic metabolism and in steroidogenesis.
One interpretation is that the CYP450 enzymes contrib-
uted to processes downstream of monoester formation
and may be less representative of the monoester biologic
actions and more representative of non-specific placental
metabolism and function. In the absence of empirical
knowledge of how the monoester and oxidative metabo-
lites compare in their direct vs. indirect effects on devel-
opmental pathways in the placenta, we erred on the side
of caution in our modeling strategy.
A limitation of the study was the fact that our sample
size was too small to formally test the placental medi-
ation hypothesis of exposure and outcome, especially in
the setting of interactions with sex. Parameter estimates
may be imprecise due to sample size and due to the
difficulties in quantifying mRNA levels in a clinical study
using high-throughput methods as we have done here.
Given that we had to employ field study methods to
sample these placentas at 3 hospitals, we could not
maintain tight control on the time elapsed between
delivery and tissue sampling. We collected information
on time and controlled for it in the analysis. Another
limitation was reliance on the birth record for our
outcomes and inability to confirm these diagnoses
according to physiologic parameters. To assess exposure,
we had to rely on a single urine sample collected in the
third trimester which can be adequate for MnBP, MBzP
and MiBP (intraclass correlation coefficient [ICC] >0.5)
but less optimal for MEHP, MEOHP, MEHHP, MECPP,
MEP and MCPP (ICC < 0.5) [3, 63].
Conclusions
We report evidence of sex-specific associations of
phthalate exposure and placental gene expression at the
level of single genes involved in hCG (and other placen-
tal hormone) synthesis and regulation (CGA, CYP19A1,
CYP11A1), adipogenesis and metabolic programming
(PPARG), xenobiotic sensing (AHR), trophoblast differ-
entiation (PPARG, CGA), lipid transport (PPARG). We
presented additional support for this finding at the level
of the secreted hCG protein early in pregnancy [20]. In a
companion manuscript, we report partial confirmation
of the findings reported here using in vitro models of
the early human placenta (Adibi et al. in review). These
findings are a first step towards establishing a biologic
basis for the associations reported between these same
prenatal concentrations and developmental outcomes at
3,5,7, and 8 years of life. Future studies will consider
these placental biomarkers as mediators of prenatal
phthalate concentrations and developmental outcomes
in the children.
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